Myelodysplastic Syndrome
News
FDA OKs new agent to block chemotherapy-induced neutropenia
Efbemalenograstim has been approved by the FDA to combat infections in adults being treated for nonmyeloid cancers.
From the Journals
Study confirms small blood cancer risk from CT scans
New research suggests that radiation exposure from CT scans heightens the risk of blood cancer in people under age 22.
News
FDA OKs ivosidenib for IDH1-mutated myelodysplastic syndromes
For adults with a rare form of myelodysplastic syndromes, the FDA has approved a targeted therapy called ivosidenib.
Conference Coverage
Using JAK inhibitors for myelofibrosis
Newer options are improving management of cytopenic patients.
Conference Coverage
CHP/CCUS: Low blood cancer risk for most patients
The goal of ongoing research is to prevent CHIP/CCUS progression in higher-risk patients.
From the Journals
ESMO helps hematologists assess new cancer drugs
The group’s new study evaluation tool, the ESMO-MCBS:H, is aimed at helping doctors and others determine the benefit of new blood cancer therapies...
Conference Coverage
Multiprong strategy makes clinical trials less White
Only a small percentage of eligible patients participate in clinical trials in the first place, and very few come from racial and ethnic minority...
Conference Coverage
CBSM phone app eases anxiety, depression in cancer patients
Few patients with cancer have access to psycho-oncologic support.
Feature
Drugmakers are abandoning cheap generics, and now U.S. cancer patients can’t get meds
On Nov. 22, three FDA inspectors arrived at the sprawling Intas Pharmaceuticals plant south of Ahmedabad, India, and found hundreds of trash bags...
Conference Coverage
CMML: GM-CSF inhibitor lenzilumab shows early promise
The PREACH-M trial has yielded encouraging preliminary results in treating CMML, a rare, “insidious” leukemia that can transform into AML.
Conference Coverage
'Paradigm shift’: Luspatercept for MDS
In a first head-to-head comparison study, luspatercept for MDS significantly outperformed epoetin alfa in reducing transfusion dependence.